PMD Healthcare Supports & Connects Patients During CF Awareness Month

ALLENTOWN, Pa., May 22, 2017 /PRNewswire/ -- Cystic Fibrosis is a life threatening chronic illness that causes persistent lung infections and limits ones ability to breathe over time. CF affects approximately 70,000 adults and children around the world and although life expectancy has doubled in the last 30 years, hundreds still die from this disease on a daily basis.

May is Cystic Fibrosis Awareness Month and PMD Healthcare believes in the continued support of advocacy and education regarding the disease. 

Dr. Gary McPhail, MD, Director of the Cystic Fibrosis Center at Cincinnati Children's Hospital, explains that patients suffering from CF have one of the highest burdens of treatment. Everyday, those with CF have to complete multiple hours of lung therapy and take dozens of medications. This makes it difficult for patients to maintain a normal life and go to school, to work or have an active social life. "Time management of the care plan can be the trickiest part of treatment," says McPhail.

Home monitoring devices can help to ease the burden of treatment by offering patients real-time results without having to travel to their physician's office and wait for their results. "Home monitoring is a trend that all people are getting into with Apple Watches and FitBits, not just those suffering from chronic illness," said McPhail. Home monitoring can connect patients and their physician remotely, enabling physicians to track the patient's progress more closely and on a continual basis without trips to the hospital or clinic.

Founded in 2010, PMD Healthcare is a Medical Device, Digital Health, and Chronic Care Management Service Company with a mission dedicated to creating innovative solutions that empower people to improve their healthcare and quality of life. With that intent focus, PMD developed the first ever personal spirometer, Spiro PD, which was approved by the FDA in 2011.  Since then, Spiro PD has been widely adopted by leading healthcare institutions and has become the standard of care for remote monitoring of lung function for patients who have undergone lung transplant surgery and for patients with cystic fibrosis.

PMD is now launching several new products including its second-generation spirometer, Spiro PD 2.0, and its HIPPA compliant Wellness Management System (WMS). The introduction of the second-generation Spiro PD 2.0 device and HIPPA compliant Wellness Management System (WMS) introduces the use of telemonitoring technology via WIFI to connect patients, providers and caregivers anytime and anywhere. 

"Two key measures for patients with CF are lung function, FEV1, and body mass index. The Spiro PD 2.0 monitors both and records these in real-time," says Gretchen Myers, PMD Account Director.

To learn more about PMD Healthcare, please visit www.MyPMD.com.

SOURCE PMD Healthcare

Related Links

http://www.mypmd.com